Back to results
US 9,790,273 B2Granted
Anti-HLA-B*27 antibodies and uses thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAndrew J. Murphy, Ana Kostic
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAndrew J. Murphy, Ana Kostic
Estimating the term…
The present invention provides antibodies and antigen-binding fragments thereof that specifically bind HLA-B*27 (also called HLA-B27). In certain embodiments, the antibodies of the invention bind soluble and/or cell surface-expressed forms of HLA-B*27. The antibodies of the present invention, in certain embodiments, inhibit HLA-B*27-mediated activation of T cells. Certain exemplary antibodies of the present invention exhibit enhanced binding to HLA-B*27 as compared to other HLA-B allelic variants (e.g., HLA-B*07). The present invention also provides anti-HLA-B*27 antibodies with pH-dependent binding characteristics (e.g., higher affinity binding at neutral pH than at acidic pH). The antibodies of the invention are useful for the treatment of diseases and disorders associated with HLA-B*27 expression, including ankylosing spondylitis and other spondyloarthropathies.
An isolated antibody, or antigen-binding fragment thereof, that specifically binds HLA-B*27, wherein the antibody or antigen-binding fragment comprises the heavy and light chain complementarity determining regions (CDRs) of a heavy chain variable region/light chain variable region (HCVR/LCVR) amino acid sequence pair selected from the group consisting of:
An isolated antibody, or antigen-binding fragment thereof, that specifically binds HLA-B*27, wherein the antibody or antigen-binding fragment comprises heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.